No Data
No Data
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
Zymeworks Begins Human Trials for New Cancer Therapy Targeting Ovarian and Lung Tumors
Express News | Zymeworks: Expects to Enroll Patients at Investigator Sites in North America, Europe, and Asia-Pacific Region
Express News | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Zymeworks Price Target Raised to $18 From $16 at Citi
Zymeworks Third Quarter 2024 Earnings: Revenues Disappoint